Outcomes of transcatheter mitral valve ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification
Author(s) :
Yoon, Sung-Han [Auteur]
Whisenant, Brian K. [Auteur]
Bleiziffer, Sabine [Auteur]
Delgado, Victoria [Auteur]
Dhoble, Abhijeet [Auteur]
Schofer, Niklas [Auteur]
Eschenbach, Lena [Auteur]
Bansal, Eric [Auteur]
Murdoch, Dale J. [Auteur]
Ancona, Marco [Auteur]
Schmidt, Tobias [Auteur]
Yzeiraj, Ermela [Auteur]
Vincent, Flavien [Auteur]
Niikura, Hiroki [Auteur]
Kim, Won-Keun [Auteur]
Asami, Masahiko [Auteur]
Unbehaun, Axel [Auteur]
Hirji, Sameer [Auteur]
Fujita, Buntaro [Auteur]
Silaschi, Miriam [Auteur]
Tang, Gilbert H L. [Auteur]
Kuwata, Shingo [Auteur]
Wong, S Chiu [Auteur]
Frangieh, Antonio H. [Auteur]
Barker, Colin M. [Auteur]
Davies, James E. [Auteur]
Lauten, Alexander [Auteur]
Deuschl, Florian [Auteur]
Nombela-Franco, Luis [Auteur]
Rampat, Rajiv [Auteur]
Nicz, Pedro Felipe Gomez [Auteur]
Masson, Jean-Bernard [Auteur]
Wijeysundera, Harindra C. [Auteur]
Sievert, Horst [Auteur]
Blackman, Daniel J. [Auteur]
Gutierrez-Ibanes, Enrique [Auteur]
Sugiyama, Daisuke [Auteur]
Chakravarty, Tarun [Auteur]
Hildick-Smith, David [Auteur]
De Brito, Fabio Sandoli [Auteur]
Jensen, Christoph [Auteur]
Jung, Christian [Auteur]
Smalling, Richard W. [Auteur]
Arnold, Martin [Auteur]
Redwood, Simon R. [Auteur]
Kasel, Albert Markus [Auteur]
Maisano, Francesco [Auteur]
Treede, Hendrik [Auteur]
Ensminger, Stephan M. [Auteur]
Kar, Saibal [Auteur]
Kaneko, Tsuyoshi [Auteur]
Pilgrim, Thomas [Auteur]
Sorajja, Paul [Auteur]
Van Belle, Eric [Auteur]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011
Prendergast, Bernard D. [Auteur]
Bapat, Vinayak [Auteur]
Modine, Thomas [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Schofer, Joachim [Auteur]
Frerker, Christian [Auteur]
Kempfert, Joerg [Auteur]
Attizzani, Guilherme F. [Auteur]
Latib, Azeem [Auteur]
Schaefer, Ulrich [Auteur]
Webb, John G. [Auteur]
Bax, Jeroen J. [Auteur]
Makkar, Raj R. [Auteur]
Whisenant, Brian K. [Auteur]
Bleiziffer, Sabine [Auteur]
Delgado, Victoria [Auteur]
Dhoble, Abhijeet [Auteur]
Schofer, Niklas [Auteur]
Eschenbach, Lena [Auteur]
Bansal, Eric [Auteur]
Murdoch, Dale J. [Auteur]
Ancona, Marco [Auteur]
Schmidt, Tobias [Auteur]
Yzeiraj, Ermela [Auteur]
Vincent, Flavien [Auteur]
Niikura, Hiroki [Auteur]
Kim, Won-Keun [Auteur]
Asami, Masahiko [Auteur]
Unbehaun, Axel [Auteur]
Hirji, Sameer [Auteur]
Fujita, Buntaro [Auteur]
Silaschi, Miriam [Auteur]
Tang, Gilbert H L. [Auteur]
Kuwata, Shingo [Auteur]
Wong, S Chiu [Auteur]
Frangieh, Antonio H. [Auteur]
Barker, Colin M. [Auteur]
Davies, James E. [Auteur]
Lauten, Alexander [Auteur]
Deuschl, Florian [Auteur]
Nombela-Franco, Luis [Auteur]
Rampat, Rajiv [Auteur]
Nicz, Pedro Felipe Gomez [Auteur]
Masson, Jean-Bernard [Auteur]
Wijeysundera, Harindra C. [Auteur]
Sievert, Horst [Auteur]
Blackman, Daniel J. [Auteur]
Gutierrez-Ibanes, Enrique [Auteur]
Sugiyama, Daisuke [Auteur]
Chakravarty, Tarun [Auteur]
Hildick-Smith, David [Auteur]
De Brito, Fabio Sandoli [Auteur]
Jensen, Christoph [Auteur]
Jung, Christian [Auteur]
Smalling, Richard W. [Auteur]
Arnold, Martin [Auteur]
Redwood, Simon R. [Auteur]
Kasel, Albert Markus [Auteur]
Maisano, Francesco [Auteur]
Treede, Hendrik [Auteur]
Ensminger, Stephan M. [Auteur]
Kar, Saibal [Auteur]
Kaneko, Tsuyoshi [Auteur]
Pilgrim, Thomas [Auteur]
Sorajja, Paul [Auteur]
Van Belle, Eric [Auteur]

Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011
Prendergast, Bernard D. [Auteur]
Bapat, Vinayak [Auteur]
Modine, Thomas [Auteur]

Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Schofer, Joachim [Auteur]
Frerker, Christian [Auteur]
Kempfert, Joerg [Auteur]
Attizzani, Guilherme F. [Auteur]
Latib, Azeem [Auteur]
Schaefer, Ulrich [Auteur]
Webb, John G. [Auteur]
Bax, Jeroen J. [Auteur]
Makkar, Raj R. [Auteur]
Journal title :
European heart journal
Abbreviated title :
Eur. Heart J.
Publication date :
2018-10-23
ISSN :
1522-9645
English keyword(s) :
Annuloplasty ring
Mitral annular calcification
Mitral valve
Transcatheter valve implantation
Degenerated bioprostheses
Mitral annular calcification
Mitral valve
Transcatheter valve implantation
Degenerated bioprostheses
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
We sought to evaluate the outcomes of transcatheter mitral valve replacement (TMVR) for patients with degenerated bioprostheses [valve-in-valve (ViV)], failed annuloplasty rings [valve-in-ring (ViR)], and severe mitral ...
Show more >We sought to evaluate the outcomes of transcatheter mitral valve replacement (TMVR) for patients with degenerated bioprostheses [valve-in-valve (ViV)], failed annuloplasty rings [valve-in-ring (ViR)], and severe mitral annular calcification [valve-in-mitral annular calcification (ViMAC)]. From the TMVR multicentre registry, procedural and clinical outcomes of ViV, ViR, and ViMAC were compared according to Mitral Valve Academic Research Consortium (MVARC) criteria. A total of 521 patients with mean Society of Thoracic Surgeons score of 9.0 ± 7.0% underwent TMVR (322 patients with ViV, 141 with ViR, and 58 with ViMAC). Trans-septal access and the Sapien valves were used in 39.5% and 90.0%, respectively. Overall technical success was excellent at 87.1%. However, left ventricular outflow tract obstruction occurred more frequently after ViMAC compared with ViR and ViV (39.7% vs. 5.0% vs. 2.2%; P < 0.001), whereas second valve implantation was more frequent in ViR compared with ViMAC and ViV (12.1% vs. 5.2% vs. 2.5%; P < 0.001). Accordingly, technical success rate was higher after ViV compared with ViR and ViMAC (94.4% vs. 80.9% vs. 62.1%; P < 0.001). Compared with ViMAC and ViV groups, ViR group had more frequent post-procedural mitral regurgitation ≥moderate (18.4% vs. 13.8% vs. 5.6%; P < 0.001) and subsequent paravalvular leak closure (7.8% vs. 0.0% vs. 2.2%; P = 0.006). All-cause mortality was higher after ViMAC compared with ViR and ViV at 30 days (34.5% vs. 9.9% vs. 6.2%; log-rank P < 0.001) and 1 year (62.8% vs. 30.6% vs. 14.0%; log-rank P < 0.001). On multivariable analysis, patients with failed annuloplasty rings and severe MAC were at increased risk of mortality after TMVR [ViR vs. ViV, hazard ratio (HR) 1.99, 95% confidence interval (CI) 1.27-3.12; P = 0.003; ViMAC vs. ViV, HR 5.29, 95% CI 3.29-8.51; P < 0.001]. The TMVR provided excellent outcomes for patients with degenerated bioprostheses despite high surgical risk. However, ViR and ViMAC were associated with higher rates of adverse events and mid-term mortality compared with ViV.Show less >
Show more >We sought to evaluate the outcomes of transcatheter mitral valve replacement (TMVR) for patients with degenerated bioprostheses [valve-in-valve (ViV)], failed annuloplasty rings [valve-in-ring (ViR)], and severe mitral annular calcification [valve-in-mitral annular calcification (ViMAC)]. From the TMVR multicentre registry, procedural and clinical outcomes of ViV, ViR, and ViMAC were compared according to Mitral Valve Academic Research Consortium (MVARC) criteria. A total of 521 patients with mean Society of Thoracic Surgeons score of 9.0 ± 7.0% underwent TMVR (322 patients with ViV, 141 with ViR, and 58 with ViMAC). Trans-septal access and the Sapien valves were used in 39.5% and 90.0%, respectively. Overall technical success was excellent at 87.1%. However, left ventricular outflow tract obstruction occurred more frequently after ViMAC compared with ViR and ViV (39.7% vs. 5.0% vs. 2.2%; P < 0.001), whereas second valve implantation was more frequent in ViR compared with ViMAC and ViV (12.1% vs. 5.2% vs. 2.5%; P < 0.001). Accordingly, technical success rate was higher after ViV compared with ViR and ViMAC (94.4% vs. 80.9% vs. 62.1%; P < 0.001). Compared with ViMAC and ViV groups, ViR group had more frequent post-procedural mitral regurgitation ≥moderate (18.4% vs. 13.8% vs. 5.6%; P < 0.001) and subsequent paravalvular leak closure (7.8% vs. 0.0% vs. 2.2%; P = 0.006). All-cause mortality was higher after ViMAC compared with ViR and ViV at 30 days (34.5% vs. 9.9% vs. 6.2%; log-rank P < 0.001) and 1 year (62.8% vs. 30.6% vs. 14.0%; log-rank P < 0.001). On multivariable analysis, patients with failed annuloplasty rings and severe MAC were at increased risk of mortality after TMVR [ViR vs. ViV, hazard ratio (HR) 1.99, 95% confidence interval (CI) 1.27-3.12; P = 0.003; ViMAC vs. ViV, HR 5.29, 95% CI 3.29-8.51; P < 0.001]. The TMVR provided excellent outcomes for patients with degenerated bioprostheses despite high surgical risk. However, ViR and ViMAC were associated with higher rates of adverse events and mid-term mortality compared with ViV.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille
Submission date :
2019-11-27T14:34:53Z